Cancer Test Shows 100% Sensitivity and Specificity

The results of multisite clinical trials have shown that a new blood test for cancer detection, based on molecular fingerprinting, correctly identified 177 patients known to have lung, breast, gastrointestinal, or prostate cancer; and also correctly ruled out cancer in each of the 72 control patients.

The data were presented at Karolinska Institute (Solna, Sweden) by Dr. Toomas Neuman, chief scientific officer of CeMines, Inc. (Evergreen, CO, USA), which developed the test. Based on the data, Karolinska has initiated a 4,500 patient study of the cancer-detection technology.

"CeMines' noninvasive molecular fingerprinting technology is extremely promising, and the idea behind this approach is brilliant,” said Dr. Madis Metsis, principal investigator of the study now under way at Karolinska. "The next step will be systematic and well-defined analyses of tumors in order to reach the ultimate goal of molecular fingerprinting--deciphering the molecular structure of individual tumors that will help us design specific diagnostic methods and drugs to treat cancer.”

As part of the body's immune response to cancer, antibodies are produced to fight cancer cells. These antibodies, which reflect the molecular signature or ‘fingerprint' of a tumor, are generated in cancer's earliest stages, says CeMines, even when the tumor is a collection of single cells. CeMines' technology detects these antibodies in the blood to diagnose a variety of tumors. The detection of these antibodies could result in the discovery of cancer months, perhaps years, before today's conventional methods.




Related Links:
CeMines